Some of the most harmful genetic changes in cancer are also the hardest to see. These structural alterations, deep within a ...

A team of international researchers led by scientists at City of Hope®, one of the largest and most advanced cancer research ...

Archeus hopes to begin a Phase I trial of the PSMA-targeted agent in metastatic, castration-resistant prostate cancer later this year.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

The EMA has given a positive opinion for the exceptional circumstances authorization of Imreplys (sargramostim) to treat myelosuppression after acute radiation exposure.

EULAR now recommends moving directly to biologic or targeted synthetic disease-modifying antirheumatic drugs if the initial ...

Researchers at Araris Biotech AG have developed antibody-drug conjugate (ADC) technology that allows single-step connection of antibody to drug via a novel RKAA peptide linker that stably prevents the ...

Dr. Joshua K. Sabari and Dr. Julia E. McGuinness discussed the SERENA-6 trial and its outcomes for patients with ESR1-mutated HR+/HER2— breast cancer.

SENTI-202, a groundbreaking CAR NK-cell therapy, targets relapsed/refractory AML, offering hope for patients with limited ...

In a busy reporting day for biotechs, Orthocell reports promising results of a follow-up study of its nerve repair device Remplir.

Teva’s experimental anti-PD1-IL2 ATTENUKINE therapy is designed to selectively deliver interleukin-2 to PD-1-expressing T ...

TEVA teams up with Fosun to speed the development of TEV-56278, a novel anti-cancer immunotherapy targeting PD-1+ T cells.